论文部分内容阅读
本文对３３例经病理组织学确诊为胃癌的病人于手术前行选择性动脉插管灌注抗癌药物治疗（ＳｅｌｅｃｔｉｖｅＡｒｔｅｒｉａｌｐｅｒｆｕｓｉｏｎｃｈｍｏｔｈｅｒａｐｙＳＡＰＣ）并与同期１０例胃癌病人于术前行全身静脉化疗相比，取得近期满意疗效．在治疗组中，除临床症状有不同程度的改善外，其胃癌原发灶和淋巴结转移灶中，癌细胞均有不同程度的变性坏死，有效率分别为９５．６５％和８０％，而对照组为２０％及０％．在接受手术的２７例中，有２３例行切除术，其中有２例早期胃癌在术后病理标本中未找到癌细胞．作者认为，胃癌病人术前行ＳＡＰＣ，其近期抗癌效果好，毒副反应小，不仅可提高胃癌的手术切除率和根治率，对减少或防止术中癌细胞的医源性扩散、种植和术后复发均有重要的临床意义．
In this paper, 33 cases of patients diagnosed as gastric cancer by histopathology were treated with selective arterial perfusion chemotherapy (SAP) before surgery and compared with 10 cases of gastric cancer patients undergoing systemic intravenous chemotherapy before surgery. Efficacy. In the treatment group, in addition to the improvement of clinical symptoms in different degrees, in the primary gastric cancer and lymph node metastases, the cancer cells had varying degrees of degeneration and necrosis, the effective rates were 95.65% and 80%, respectively. The group is 20% and 0%. Of the 27 patients undergoing surgery, 23 underwent resection. Among them, 2 cases of early gastric cancer did not find cancer cells in postoperative pathological specimens. The authors believe that preoperative SAPC in gastric cancer patients has good anti-cancer effects and low toxicities. It can not only improve the surgical resection rate and radical cure rate of gastric cancer, but also reduce or prevent the iatrogenic proliferation and planting of cancer cells in the operation. Postoperative recurrence has important clinical significance.